European biotech needs specialized capital and stronger continuity across funding stages to get to the next level, writes ...

Novo Nordisks Aleksandar Ciric writes that leaders can apply sports principles such as speed of action, clarity, and ...

Clinical development costs are rising due to the disruption of shipping routes in the Strait of Hormuz, writes Mathini ...

Speed alone no longer guarantees success; here’s what matters most in today’s launch environment. In today’s launch environment, order of entry (OOE) isn’t destiny. Many brands still anchor strategy ...

New York City-based Volastra Therapeutics – whose founders and scientific advisors are leading chromosomal instability researchers and experts – have in four years’ time advanced two drug candidates ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

Marc Richards Biotechnology companies often offer a promise of future success, but it can take years to determine whether all the effort (and expense) will translate into returns. Because of the ...

Patient safety is the top priority for regulators. While the industry and the public advocate for alternatives to animal testing, regulators require strong evidence that alternatives are equally safe ...

KeifeRx has a full range of neuroscience (NS) drug candidates in development, spanning later-stage clinical assets to several novel, pre-IND technologies. Nilotinib (coded KFRX01) is close to entering ...

Spinning off a $4 billion biopharma business is no easy task. Integrated functions need to be separated, governance boards created, leadership teams assembled, and corporate headquarters established.

I’ve spent most of my career in life sciences, and like many in the field, I’ve seen how slow and cautious the industry can be when embracing new technology. It’s understandable. We work in a highly ...

Implementing AI in drug discovery offers significant potential for reducing operating costs, though the extent varies widely. A Deloitte report suggests AI could cut drug development costs by up to 70 ...